|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 111.06 USD | -0.64% |
|
-0.60% | +20.23% |
| 07-07 | RBC Lifts Price Target on Gilead Sciences to $96 From $95, Keeps Sector Perform Rating | MT |
| 07-02 | Gilead Sciences Insider Sold Shares Worth $1,104,484, According to a Recent SEC Filing | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability (Composite) | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
| 139B | ||||||
| 694B | ||||||
| 374B | ||||||
| 331B | ||||||
| 308B | ||||||
| 259B |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition